Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2019 - 2026)

Zentalis Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 187.78% year-over-year to -$1.2 billion in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 187.78% decrease from a year earlier, with the FY2025 full-year figure at $196000.0, up 100.02% from the prior year.
• Retained Earnings retreated to -$1.2 billion in Q1 2026 per ZNTL's latest filing, from $196000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $1.4 billion in Q1 2025 and bottomed at -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$1.4 million (2022), against an average of -$149.3 million.
• Across the five-year window, Retained Earnings surged 1469894.0% in 2022 and plunged 157901.44% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$1.4 million in 2022, then plunged by 65573.02% to -$888.6 million in 2023, then declined by 18.66% to -$1.1 billion in 2024, then jumped by 100.02% to $196000.0 in 2025, then slumped by 626021.94% to -$1.2 billion in 2026.
• Per Business Quant, the three latest ZNTL Retained Earnings figures stand at -$1.2 billion (Q1 2026), $196000.0 (Q4 2025), and -$1.2 billion (Q3 2025).